Skip to main content
Fig. 2 | BMC Neuroscience

Fig. 2

From: Generation of a novel monoclonal antibody that recognizes the alpha (α)-amidated isoform of a valine residue

Fig. 2

Pre-absorption control assays of valine amide immunoreactivity in tissues. The panels show bright-field photomicrographs (×40) of Val-CONH2–ir in neuroendocrine glands and sagittal sections of the rat brain using the specific PC18C5 mAb. Panel a illustrates the expression of Val-CONH2–ir in the pituitary gland before (left panel) and after pre-absorption with 10 μM of the isovariant of the valine residue (Val-CONH2) (right panel). Note the absence of PC18C5 mAb-ir in the tissue after treatment with the Val-CONH2 residue. NL neural lobe, IL intermediate lobe, AL anterior lobe (red arrows). Panel b illustrates the expression of Val-CONH2-ir in the adrenal gland before (left panel) and after pre-absorption with 10 μM of the isovariant Val-CONH2 (right panel). PC18C5 mAb-ir was localized to the core region of the adrenal gland (me) (red arrow). Panel c shows the expression of Val-CONH2-ir in a representative sagittal section of the rat brain before (left panel) and after pre-absorption with 10 μM of the isovariant Val-CONH2 (right panel). The intensity of immunoreactive signals was arbitrarily graded using a scale previously described in [45] (see text for additional details). Scale bar = ×40

Back to article page